Stroke drug urokinase gets safety check in new trial
NCT ID NCT07047326
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study aims to find the safest and most effective dose of urokinase, a clot-busting drug, for people having an acute ischemic stroke. Researchers will enroll 24 adults aged 18-80 who can receive treatment within 6 hours of symptoms starting. The goal is to develop a weight-based dosing plan that maximizes benefit while minimizing bleeding risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100053, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.